Highlight
- Baveno VI criteria show suboptimal accuracy for ruling out varices in patients with hepatocellular carcinoma (HCC) and compensated advanced chronic liver disease (cACLD).
- SAPHE-R, a new non-invasive rule incorporating liver stiffness measurement (LSM), ALBI grade, and platelet count, improves varices exclusion with fewer missed cases than Baveno VI.
- SAPHE-R reduces the need for invasive upper gastrointestinal endoscopy (UGE), sparing approximately 18% of procedures without compromising safety.
- External validation confirms SAPHE-R’s robustness, offering a reliable clinical tool for variceal risk stratification in HCC.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
